Enoxaparin may be safe for patients with cancer, brain metastases
the ONA take:
According to a new study published online in the journal Blood, researchers have found that patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin, a type of low molecular weight heparin anticoagulant, without increased risk of intracranial hemorrhage.
For the study, researchers sought to assess the risk of intracranial hemorrhage, a dangerous form of bleeding in the head, associated with the administration of therapeutic doses of enoxaparin.
Researchers identified 239 patients with cancer and brain metastases. Of those, 104 received therapeutic enoxaparin and 189 were their matched controls that did not receive blood-thinning treatment.
Results showed that there were no differences in the cumulative incidence of intracranial hemorrhage at 1 year in the enoxaparin and control cohorts.
Researchers found that patients with melanoma or renal cell carcinoma had a fourfold higher risk of intracranial hemorrhage than those with lung cancer, but administration of enoxaparin did not affect that risk. The study also showed that overall survival was similar in both groups.
Patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|